The pyrogen question has a price, and it is not the price of a purity run
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 4 of 67 of this archive, newest first.
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
The route did not close because of a rule about peptides.
The route did not close because of a rule about peptides.
The route did not close because of a rule about peptides.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Follow the resin, not the catalogue.
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
Reported from the analysis, not from a warning notice.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Follow the resin, not the catalogue.
The route did not close because of a rule about peptides.
Reported from the analysis, not from a warning notice.
We describe each pathway in enough chemical detail to explain why it is invisible to the method the trade uses, because that is the part which has practical consequences.
Follow the resin, not the catalogue.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
The route did not close because of a rule about peptides.
Reported from the analysis, not from a warning notice.